Legacy Advisors’s Matinas BioPharma MTNB Stock Holding History

Legacy Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$8K	–	112
2020 Q3	$8K	Buy	+200	New	+$7.95K	0.01%	109

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Legacy Advisors's MTNB Position: Q4 2020 in Review

Legacy Advisors sold out of Matinas BioPharma (MTNB) in Q4 2020, closing a stake of 200 shares — an estimated $8K sold.

Legacy Advisors first reported a position in MTNB in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 71 funds tracked by Wall St. Rank hold MTNB as of Q4 2020.

Legacy Advisors reported no remaining Matinas BioPharma position as of Q4 2020 after selling out during the quarter.
Legacy Advisors sold 200 Matinas BioPharma shares in Q4 2020, an estimated $8K.
Legacy Advisors first reported a position in Matinas BioPharma in Q3 2020 and held it in 1 quarter.
Legacy Advisors's Matinas BioPharma position peaked at $8K in Q3 2020.
71 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2020.

Based on Legacy Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.